Paraclinical diagnostics of endothelial function reflecting vascular stiffness: the present and prospects. Literature review

For many years, cardiovascular diseases remain the leading cause of death in the world. The most significant risk factor for their development is hypertension. Endothelial dysfunction is one of the central links in the pathogenetic mechanisms of the formation and progression of vascular stiffness in hypertension. That is why the identification and assessment of endothelial function is of high practical importance for practitioner.

The review aim is to analyze and summarize the available data on paraclinical diagnostics of endothelial dysfunction involved in the formation of vascular stiffness.

1. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243-50. doi:10.1161/CIRCULATIONAHA.108.797936.

2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041 doi:10.1093/eurheartj/ehy339.

3. Zhiven’ MK, Zaharova IS, Shevchenko AI, et al. A heterogeneity of en­dothelial cells. Pathol Blood Circul Card Surg. 2015;19(4-2):104-12. (In Russ.) doi:10.21688/1681-3472-2015-4-2-104-112.

4. Hirase T, Node K. Endothelial dysfunction as a cellular mecha­nism for vascular failure. Am J Physiol Heart Circ Physiol. 2012; 302(3):H499-505. doi:10.1152/ajpheart.00325.2011.

5. El-Sabban F. The endothelium and cardiovascular disease-a mini review. MOJ Anat Physiol. 2015;1(3):53-8. doi:10.15406/mojap.2015.01.00011.

6. Huang Y, Rabb H, Womer KL. Ischemiareperfusion and immediate T cell responses. Cell Immunol. 2007;248(1):4-11. doi:10.1016/j.cellimm.2007.03.009.

7. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg. 2002; 10(6):620-30. doi:10.1016/s0967-2109(02)00070-4.

8. Tesauro M, Mauriello A, Rovella V, et al. Arterial ageing: from endo­thelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):47182. doi:10.1111/joim.12605.

9. Cunha PG, Cotter J, Oliveira P, et al. Pulse wave velocity distri­bution in a cohort study: from arterial stiffness to early vas­cular aging. J Hypertens. 2015;33(7):143845. doi:10.1097/HJH.0000000000000565.

10. Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65:2526. doi:10.1161/HYPERTENSIONAHA.114.03617.

11. Kushakovsky M. Essential hypertension (hypertension): Causes, mechanisms, clinic, treatment. 5. ed., substantially additional and revised St. Petersburg: Folio, 2002. p.414. (In Russ.) ISBN: 5-93929-045-0.

12. Jin Y, Ji W, Yang H, et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5(1):293. doi:10.1038/s41392-020-00454-7.

13. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive de­tection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111-5. doi:10.1016/0140-6736(92)93147-f.

14. Joannides R, Haefeli WE, Linder L, et al. Role of nitric oxide in flow-dependent vasodilation of human peripheral arteries in vivo. Arch Mal Coeur Vaiss. 1994;87(8):983-5.

15. Drapkina OM, Fadeeva MV. Arterial aging as a cardiovascular risk factor. "Arterial’naya Gipertenziya" ("Arterial Hyper­ten­sion"). 2014;20(4):224-31. (In Russ.) doi:10.18705/1607-419X-2014-20-4-224-231.

16. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol. 1995;26:1235-41. doi:10.1016/0735-1097(95)00327-4.

17. Zhatkina MV, Gavrilova NE, Makarova YuK, et al. Diagnosis of multifocal atherosclerosis using the Celermajer test. Cardiovascular Therapy and Prevention. 2020;19(5):2638. (In Russ.) doi:10.15829/1728-8800-2020-2638.

18. Millasseau SC, Kelly RP, Ritter JM, et al. Determination of age related increases in large artery stiffness by digital pulse contour analysis. Clin Sci. 2002;103:371-7. doi:10.1042/cs1030371.

19. Chowienczyk PJ, Kelly RP, MacCallum H, et al. Photo plethysmographic assessment of pulse wave reflection. Blunted response to endotheliumdependent beta-2-adrenergic vasodilation in type II diabetes mellitus. J Am Coll Cardiol. 1999;34:2007-14. doi:10.1016/s0735-1097(99)00441-6.

20. Laucevicius A, Ryliskyte L, Petruioniene Z, et al. First expe rience with salbutomol — induced changes in the photo plethysmogaphic digital volume pulse. Semin Cardiol. 2002;8:87-93.

21. Millasseau SC, Guigui FG, Kelly RP, et al. Noninvasive assessment of the digital volume pulse. Comparison with the peripheral pressure pulse. Hypertension 2000;36:952-6. doi:10.1161/01.hyp.36.6.952.

22. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121(4):505-11. doi:10.1161/CIRCULATIONAHA.109.886655.

23. Shirai K, Hiruta N, Song M, et al. Cardioankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011;18(11):924-38. doi:10.5551/jat.7716.

24. Miyoshi T, Ito H. Arterial stiffness in health and disease: The role of cardio-ankle vascular index. J Cardiol. 2021;78(6):493-501. doi:10.1016/j.jjcc.2021.07.011.

25. Kotani K, Miyamoto M, Taniguchi N. Clinical significance of the cardio-ankle vascular index (CAVI) in Hypertension. Curr Hypertens Rev. 2010;6:251-3. doi:10.2174/157340210793611659.

26. Nagayama D, Watanabe Y, Saiki A, et al. Difference in positive relation between cardio-ankle vascular index (CAVI) and each of four blood pressure indices in real-world Japanese population. J Hum Hypertens. 2019;33(3):210-7. doi: 10.1038/s41371-019-0167-1.

27. Timofeev YuS, Mikhailova MA, Dzhioeva ON, et al. Importance of biological markers in the assessment of endothelial dysfunction. Cardiovascular Therapy and Prevention. 2024;23(9):4061. (In Russ.) doi:10.15829/1728-8800-2024-4061.

28. Metel'skaya VA, Gumanova NG. Oksid azota: rol' v regulyacii biologicheskih funkcij, metody opredeleniya v krovi cheloveka. Lab med. 2005;7:19-24. (In Russ.)

29. Gumanova NG, Klimushina MV, Metel'skaya VA. Optimization of Single-Step Assay for Circulating Nitrite and Nitrate Ions (NOx) as Risk Factors of Cardiovascular Mortality. Bull Exp Biol Med. 2018;165(2):284-7. doi:10.1007/s10517-018-4149-z.

30. Landim MB, Casella Filho A, Chagas AC. Asymmetric dime­thyl­arginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo). 2009;64(5):471-8. doi:10.1590/s1807-59322009000500015.

31. Berns SA, Kashtalap VV. Endothelial protective effect of pitavastatin. Cardiovascular Therapy and Prevention. 2023;22(8): 3671. (In Russ.) doi:10.15829/1728-8800-2023-3671.

32. Ageyev FT, Ovchinnikov AG, Mareyev VYu, et al. Endothelial dys­function and heart failure: a pathogenetic relationship and the potential for therapy with angiotensin converting enzyme inhibitors. Consilium medicum. 2001;3(2):61-3. (In Russ.)

33. Avtandilov AG, Libov IA, Kiselev MV, et al. Prognostic role of en­do­thelin-1 and possibilities of its correction in atients with unstable angina. Russian Medical Journal. 2008;4:211-7. (In Russ.)

34. Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116(17):1896-906. doi:10.1161/CIRCULATIONAHA.106.684852.

35. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx da­mage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55:1127-32. doi:10.2337/diabetes.55.04.06.db05-1619.

36. Neves FM, Meneses GC, Sousa NE, et al. Syndecan1 in acute decompensated heart failureassociation with renal function and mortality. Circ J. 2015;79(7):1511-9. doi:10.1253/circj.CJ-14-1195.

37. Fornai F, Carrizzo A, Forte M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016; 13(1):25. doi:10.1186/s12979-016-0080-1.

38. Liu H, Guo X, Yao K, et al. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure. Biomed Res Int. 2015:817615. doi:10.1155/2015/817615.

39. Yamasaki K, Kurimura M, Kasai T, et al. Determination of physio­logical plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47(4):4717. doi:10.1515/CCLM.2009.110.

40. Keeley FW, Alatawi A. Response of aortic elastin synthesis and accumulation to developing hypertension and the inhibitory effect of colchicine on this response. Lab Invest. 1991;64(4):499-507.

41. Neshkova EA, Metelskaya VA, Timofeev YuS, et al. Neutrophil elastase as a promising biomarker of low-grade inflammation in chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;28(4):142-8. (In Russ.) doi:10.17116/profmed202528041142.

42. Mahmoud RA, el-Ezz SA, Hegazy AS. Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital J Biochem. 2004;53(2):73-81.

43. Zhang PA, Wu JM, Li Y, et al. Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population. World J Gastroenterol. 2005;11(11):1594-8. doi:10.3748/wjg.v11.i11.1594.

44. Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and di­sease. Int J Mol Sci. 2019;20(3):649. doi:10.3390/ijms20030649.

45. O'Brien LC, Mezzaroma E, Van Tassell BW, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med. 2014;20(1):221-9. doi:10.2119/molmed.2014.00034.

46. Güntürk EE, Güntürk İ, Topuz AN, et al. Serum interleukin-18 levels are associated with non-dipping pattern in newly diagnosed hypertensive patients. Blood Press Monit. 2021;26(2):87-92. doi:10.1097/MBP.0000000000000487.

47. De Mayer G, Herman A. Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;49:325-42. doi:10.1016/s0033-0620(97)80031-x.

48. Calder PC, Ahluwalia N, Albers R, et al. A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br J Nutr. 2013;109(Suppl 1):S1e34. doi:10.1017/S0007114512005119.

49. Stepanova TV, Ivanov AN, Terechkina NE, et al. Markers of endothelial dysfunction: pathogenetic role and diagnostic significance (literature review). Clinical laboratory diagnostics. 2019;64(1):34-41. (In Russ.) doi:10.18821/OB69-20190-64-1-34-41.

50. Kulik EG, Pavlenko VI, Naryshkina SV. Von Willebrand factor and vascular endothelial dysfunction in patients with chronic obstructive pulmonary disease. Amur Medical Journal. 2017; 1(17):41-3. (In Russ.) doi:10.22448/amj.2017.17.41-43.

51. Putilina MV. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. S. S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):122-30. (In Russ.) doi:10.17116/jnevro2017117101122-130.

52. Zhao X, Yang S, Lei R, et al. Clinical study on the feasibility of new thrombus markers in predicting massive cerebral infarction. Front Neurol. 2023;13:942887. doi:10.3389/fneur.2022.942887.

53. Li F, Yuan L, Shao N, et al. Changes and significance of vascular endothelial injury markers in patients with diabetes mellitus and pulmonary thromboembolism. BMC Pulm Med. 2023;23(1):183. doi:10.1186/s12890-023-02486-5.

54. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006;373(1-2):17-26. doi:10.1016/j.cca.2006.05.016.

55. Petrishchev NN, Berkovich OA, Vlasov TD, et al. Diagnostic value of determination of desquamated endothelial cells in the blood. Klinicheskaya i laboratornaya diagnostika. 2001;(1):50-2. (In Russ.)